Your browser doesn't support javascript.
Immediate Adverse Events Following COVID-19 Vaccination in Australian Pharmacies: A Retrospective Review.
Gallo, Alexander T; Scanlon, Lisa; Clifford, Jade; Patten-Williams, Lawson; Tweedie, Lachlan; Li, Dani; Salter, Sandra M.
  • Gallo AT; Discipline of Pharmacy, School of Allied Health, University of Western Australia, Crawley 6009, Australia.
  • Scanlon L; MedAdvisor International, Camberwell 3124, Australia.
  • Clifford J; Discipline of Pharmacy, School of Allied Health, University of Western Australia, Crawley 6009, Australia.
  • Patten-Williams L; Discipline of Pharmacy, School of Allied Health, University of Western Australia, Crawley 6009, Australia.
  • Tweedie L; Discipline of Pharmacy, School of Allied Health, University of Western Australia, Crawley 6009, Australia.
  • Li D; MedAdvisor International, Camberwell 3124, Australia.
  • Salter SM; Discipline of Pharmacy, School of Allied Health, University of Western Australia, Crawley 6009, Australia.
Vaccines (Basel) ; 10(12)2022 Nov 29.
Article in English | MEDLINE | ID: covidwho-2143792
ABSTRACT

BACKGROUND:

Four COVID-19 vaccines are approved for use in Australia Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax), and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine the type and management of immediate adverse events following immunisation (I-AEFI) after COVID-19 vaccination.

METHODS:

Retrospective review of I-AEFI recorded between July 2021 and June 2022 in 314 community pharmacies in Australia.

RESULTS:

I-AEFI were recorded in 0.05% (n = 526/977,559) of all COVID-19 vaccinations (highest AstraZeneca (n = 173/161,857; 0.11%); lowest Pfizer (n = 50/258,606; 0.02%)). The most common reactions were (1) syncope, after the first dose of AstraZeneca (n = 105/67,907; 0.15%), Moderna (n = 156/108,339; 0.14%), and Pfizer (n = 22/16,287; 0.14%); and (2) Nausea/vomiting after the first dose of Pfizer (n = 9/16,287; 0.06%), Moderna (n = 55/108,339; 0.05%), and AstraZeneca (n = 31/67,907; 0.05%) vaccines. A total of 23 anaphylactic reactions were recorded (n = 23/977,559; 0.002%), and 59 additional I-AEFI were identified using MedDRA® terminology. Pharmacists primarily managed syncope by laying the patient down (n = 227/342; 66.4%); nausea/vomiting was managed primarily by laying the patient down (n = 62/126; 49.2%), giving water (n = 38/126; 30.2%), or monitoring in the pharmacy (n = 29/126; 23.0%); anaphylactic reaction was treated with adrenaline (n = 18/23; 78.3%) and n = 13/23 (56.5%) anaphylactic reactions were treated with the combination of administered adrenaline, called ambulance, and laid patient down.

CONCLUSION:

The most commonly recorded I-AEFI was syncope after COVID-19 vaccination in pharmacy; I-AEFI are similar to those previously reported. Pharmacists identified and managed serious and non-serious I-AEFI appropriately and comprehensively.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10122041

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10122041